Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;31(11):1164-1173.
doi: 10.1002/pds.5514. Epub 2022 Aug 15.

A cohort study to assess risk of cutaneous small vessel vasculitis among users of different oral anticoagulants

Adebola Ajao  1 , Austin Cosgrove  2 , Efe Eworuke  1 , Mohamed Mohamoud  3 , Rongmei Zhang  4 , Oren Shapira  2 , Joy Kolonoski  2 , John G Connolly  2
Affiliations

A cohort study to assess risk of cutaneous small vessel vasculitis among users of different oral anticoagulants

Adebola Ajao et al. Pharmacoepidemiol Drug Saf. 2022 Nov.

Abstract

Purpose: Cutaneous small vessel vasculitis (CSVV) was identified as a safety signal among patients treated with direct oral anticoagulants (DOAC). This study aimed to determine if CSVV risk differed among patients with atrial fibrillation (Afib) who newly initiated warfarin or a DOAC.

Methods: We identified enrollees aged ≥21 years diagnosed with Afib who newly initiated rivaroxaban, dabigatran, apixaban, and warfarin in the Sentinel Distributed Database from October 19, 2010 to February 29, 2020. We selected and followed patients who did not have evidence of the following in the 183 days prior to initiating treatment: CSVV diagnosis, dispensing of other study drugs, select autoimmune diseases or autoimmune medications, cancer diagnoses or chemotherapeutic treatment, kidney dialysis or transplant, alternative anticoagulation indications, or an institutional (nursing home, hospice, hospital) stay on the treatment initiation date (index date) until CSVV outcome or pre-specified censoring. We conducted 1:1 propensity score matching in six comparisons.

Results: CSVV incidence rates for DOACs and warfarin ranged from 3.3 to 5.6 per 10 000-person years in our matched Afib population. The adjusted CSVV hazard ratio (HR) and 95% confidence interval (CI) was 0.94 (0.64, 1.39) for rivaroxaban versus warfarin; 1.17 (0.67, 2.06) for dabigatran vs. warfarin; 0.85 (0.62, 1.16) for apixaban vs. warfarin; 0.86 (0.49, 1.50) for rivaroxaban vs. dabigatran; 0.99 (0.68, 1.45) for rivaroxaban versus apixaban; and 1.70 (0.90, 3.21) for dabigatran versus apixaban.

Conclusion: We did not find significant evidence of differential CSVV risk in pair-wise comparisons of DOACs and warfarin.

Keywords: atrial fibrillation; cutaneous small vessel; direct oral anticoagulants; vasculitis; vasculitisanticoagulants.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors declare no conflicts of interest.

References

    1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65(1):1–11. - PubMed
    1. Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol 2008;9(2):71–92. - PubMed
    1. Goeser MR, Laniosz V, Wetter DA. A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis. Am J Clin Dermatol 2014;15(4):299–306. - PubMed
    1. Grau RG. Drug-Induced Vasculitis: New Insights and a Changing Lineup of Suspects. Curr Rheumatol Rep 2015;17(12):71. - PubMed
    1. Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990;33(8):1065–1067. - PubMed

Publication types